USPSTF now advises biennial breast cancer screening from age 40 to 74 years based on an evolving evidence base.

AEYE Health receives clearance for the first artificial intelligence solution to allow fully autonomous screening for diabetic retinopathy using a portable device.

Experts continue their discussion of gene therapy, highlighting safety concerns and the need for more trials and data.

Findings highlight an increase in hospitalization among pregnant patients with HCV, further describing age’s impact on mortality, cirrhosis, preterm births, and stillbirths.

Experts shift to the prospect of gene therapy in treating retinal diseases.

This segment of the latest Lungcast episode featured a discussion over the ALA’s State of the Air Report and the impacts of particle pollution.

Demographic, psychosocial, and clinical factors—along with patient-provider relationships—all impact medication adherence and patient satisfaction with RA treatment.

This April 2024 month in review highlights World IBS Day, updates in the gastroenterology pipeline, ACP Internal Medicine meeting coverage, and recent IBD research.

Findings indicated treatment with colchicine resulted in a significant reduction in mortality rate compared with placebo or standard care.

Monosodium urate deposits significantly increased the risk of major cardiovascular events in patients with gout and hyperuricemia.

Internal dysbiosis was present in 66% of patients at baseline and was more common among those with a disease duration of > 2 years.

A combination of telemedicine and in-person visits led to a nearly 6% increase in electronic health record work for primary care physicians.

These data allow for a basis for additional research and possible interventions to address psoriasis patients’ demodicosis risk.

Key Opinion Leaders address the psychiatric issues associated with hypercortisolism and highlight crucial clinical symptoms to look for when diagnosing the condition, such as hypertension in patients under 30 without a family history, diabetes in those under 40 with no family history, and bone issues among other signs.

Medical experts underscore disparities in diabetes treatment access, stressing the impact of insurance plans on treatment decisions, which can hinder patients and providers, especially when considering newer medications like GLP-1 agonists.

Daniel Gaudet, MD, PhD, discusses SHASTA-2 data and what cardiologists could learn from the forthcoming 48-week MUIR trial data from EAS 2024.

FDA issued a CRL the abbreviated new drug application of ketamine, which had sought to enhance accessibility to the limited drug supply.

Abbott's Esprit BTK System was shown to significantly reduce risk of ischemic events in patients with PAD versus angioplasty over 1 year.

FDA approves mavorixafor (XOLREMDI) for WHIM syndrome, the first approved treatment for the rate disease.

Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars.

Barratt explained findings from the phase 2b ORIGIN trial of atacicept and how it compares to current standard therapies in IgAN and other agents in the pipeline.

Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar.

The announcement by Dermavant followed positive findings from the ADORING trials on tapinarof and an open label extension for children aged 2 - 17.

A new study found a 2-week mindfulness-based intervention for patients with psoriasis does not improve skin status—it only helps the mind.

A recent study found breast arterial calcification on mammograms could help predict higher risk of stroke, cardiovascular death, and heart disease in women.